Vaccines against bacterial meningitis

British Medical Bulletin

Volumn 72, Issue , 2004, Pages 65-81

  Segal, S ^a   Pollard, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; LIVE VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN VESICLE VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

BACTERIAL GENOME; BACTERIAL MENINGITIS; DEVELOPING COUNTRY; DRUG COST; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; INFECTION PREVENTION; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS;

BACTERIAL PROTEINS; BACTERIAL VACCINES; HAEMOPHILUS VACCINES; HUMANS; MENINGITIS, BACTERIAL; MENINGITIS, HAEMOPHILUS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 19044391765     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/ldh041     Document Type: Review

References (101)

1. Greenwood B (1999) The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 354, 777-85.
2. Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME (1996) Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ, 312, 160-1
3. Laurichesse H, Grimaud O, Waight P, Johnson AP, George RC, Miller E (1998) Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Commun Dis Public Health, 1, 22-7.
4. O'Dempsey TJ, McArdle TF, Lloyd-Evans N et al. (1994) Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis J, 13, 122-8.
5. Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev, 13, 302-17.
6. Quagliarello VJ, Scheld WM (1993) New perspectives on bacterial meningitis. Clin Infect Dis, 17, 603-10.
7. von Reyn CF, Vuola JM (2002) New vaccines for the prevention of tuberculosis. Clin Infect Dis, 35, 465-74.
8. Smith AW, Bradley AK, Wall RA et al. (1988) Sequelae of epidemic meningococcal meningitis in Africa. Trans R Soc Trop Med. Hyg, 82, 312-20.
9. Davison KL, Ramsay ME (2003) The epidemiology of acute meningitis in children in England and Wales. Arch Dis Child, 88, 662-4.
10. Adams WG, Deaver KA, Cochi SL et al. (1993) Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA, 269, 221-6.
11. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T (1999) Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine, 18, 736-42.
12. Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J, 17, S117-22.
13. Eskola J, Kayhty H, Takala AK et al. (1990) A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med, 323, 1381-7.
14. Ward J, Brenneman G, Letson GW, Heyward WL (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H.influenzae Vaccine Study Group. N Engl J Med, 323, 1393-1401.
15. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM (1998) Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H.influenzae type b among Gambian children. J Infect Dis, 177, 1758-61.
16. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER (1997) Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child, 77, 488-92.
17. McVernon J, Andrews N, Slack MP, Ramsay ME (2003) Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet, 361, 1521-3.
18. McVernon J, Heath P (2003) Re-inforcement of Hib immunisation required. Commun Dis Public Health, 6, 2.
19. Claesson BA, Schneerson R, Lagergard T et al. (1991) Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at, 3, 5 and 12 months of age. Pediatr Infect Dis J, 10, 560-4.
20. Claesson BA, Trollfors B, Anderson PW et al. (1996) Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J, 15, 170-2.
21. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Meningococcal disease. N Engl J Med, 344, 1378-88.
22. Cartwright K, Noah N, Peltola H (2000) Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine, 19, 4347-56.
23. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg, 93, 341-53.
24. Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet, 359, 1829-31.
25. Morley SL, Pollard AJ (2001) Vaccine prevention of meningococcal disease, coming soon? Vaccine, 20, 666-87.
26. Taha MK, Achtman M, Alonso JM et al. (2000) Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet, 356, 2159.
27. Riou JY, Djibo S, Sangare L et al. (1996) A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull WHO, 74, 181-7.
28. Vogel G (2003) Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso. Science, 299, 1499-1501.
29. Harrison LH, Pass MA, Mendelsohn AB et al. (2001) Invasive meningococcal disease in adolescents and young adults. JAMA, 286, 694-9.
30. Memish ZA, Alrajhi AA (2002) Meningococcal disease. Saudi Med J, 23, 259-64.
31. Maiden MC, Spratt BG (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet, 354, 615-16.
32. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet, 364, 365-7.
33. Miller MA, Wenger J, Rosenstein N, Perkins B (1999) Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J, 18, 1051-9.
34. Dull P, Rosenstein N (2001) Meningococcal disease and vaccines. Pediatr Ann, 30, 358-61.
35. Perkins BA, Broome CV, Rosenstein NE, Schuchat A, Reingold AL (1997) Meningococcal vaccine in sub-Saharan Africa. Lancet, 350, 1708-10.
36. Taha MK, Parent Du Chatelet I, Schlumberger M et al. (2002) Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002;40, 1083-4
37. Finne J, Leinonen M, Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet, 2, 355-7.
38. Rosenstein NE, Fischer M, Tappero JW (2001) Meningococcal vaccines. Infect Dis Clin North Am, 15, 155-69.
39. Oliver KJ, Reddin KM, Bracegirdle P et al. (2002) Neisseria lactamica protects against experimental meningococcal infection. Infect Immun, 70, 3621-6.
40. Sanchez S, Troncoso G, Criado MT, Ferreiros C (2002) In vitro induction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica. Vaccine, 20, 2957-63.
41. Tondella ML, Popovic T, Rosenstein NE et al. (2000) Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol, 38, 3323-8.
42. Fusco PC, Michon F, Tai JY, Blake MS (1997) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis, 175, 364-72.
43. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine, 22, 1087-96.
44. Nedelec J, Boucraut J, Gamier JM, Bernard D, Rougon G (1990) Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. J Neuroimmunol, 29, 49-56.
45. Tappero JW, Lagos R, Ballesteros AM et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA, 281, 1520-7.
46. de Kleijn ED, de Groot R, Labadie J et al. (2000) Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine, 18, 1456-66.
47. Boslego J, Garcia J, Cruz C et al. (1995) Efficacy, safety, and immunogenicity of a meningococcal group B (15, P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine, 13, 821-9.
48. Jodar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet, 359, 1499-1508.
49. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun, 72, 5955-62.
50. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D (1999) Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun, 67, 4955-9.
51. Parkhill J, Achtman M, James KD et al. (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature, 404, 502-6.
52. Tettelin H, Saunders NJ, Heidelberg J et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science, 287, 1809-15.
53. Jennings MP, Srikhanta YN, Moxon ER et al. (1999) The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology, 145, 3013-21.
54. Pizza M, Scarlato V, Masignani V et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 287, 1816-20.
55. Poolman J, Berthet FX (2001) Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine, 20 (Suppl 1), S24-6.
56. Grandi G (2001) Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol, 19, 181-8.
57. Sun YH, Bakshi S, Chalmers R, Tang CM (2000) Functional genomics of Neisseria meningitidis pathogenesis. Nat Med, 6, 1269-73.
58. Dawson KG, Emerson JC, Burns JL (1999) Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J, 18, 816-22.
59. Djuretic T, Ryan MJ, Miller E, Fairley CK, Goldblatt D (1998) Hospital admissions in children due to pneumococcal pneumonia in England. J Infect, 37, 54-8.
60. Shinefield HR, Black S (2000) Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J, 19, 394-7.
61. Shinefield HR, Black S, Ray P et al. (1999) Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J, 18, 757-63.
62. Black S, Shinefield H, Fireman B et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J, 19, 187-95.
63. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F (2001) Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J, 20, 1105-7.
64. Eskola J, Kilpi T, Palmu A et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med, 344, 403-9.
65. Pelton SI, Dagan R, Gaines BM et al. (2003) Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine, 21, 1562-71.
66. Poolman JT (2004) Pneumococcal vaccine development. Expert Rev Vaccines, 3, 597-604.
67. Lipsitch M (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis, 5, 336-45.
68. Lipsitch M (2001) Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. Am J Epidemiol, 154, 85-92.
69. Obaro SK (2000) Confronting the pneumococcus: a target shift or bullet change? Vaccine, 19, 1211-17.
70. Mulholland EK (2000) Conjugate pneumococcal vaccines: an overview. Med J Aust, 173 (Suppl), S48-50.
71. Lipsitch M, Dykes JK, Johnson SE et al. (2000) Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine, 18, 2895-901.
72. Hoskins J, Alborn WE Jr, Arnold J et al. (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol, 183, 5709-17.
73. Tettelin H, Nelson KE, Paulsen IT et al. (2001) Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science, 293, 498-506.
74. Dopazo J, Mendoza A, Herrero J et al. (2001) Annotated draft genomic sequence from a Streptococcus pneumoniae type 19F clinical isolate. Microb Drug Resist, 7, 99-125.
75. Jedrzejas MJ, Lamani E, Becker RS (2001) Characterization of selected strains of pneumococcal surface protein A. J Biol Chem, 276, 33121-8.
76. Jedrzejas MJ (2001) Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev, 65, 187-207.
77. Hakenbeck R, Balmelle N, Weber B, Gardes C, Keck W, de Saizieu A (2001) Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae. Infect Immun, 69, 2477-86.
78. Rosenow C, Ryan P, Weiser JN et al. (1997) Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol, 25, 819-29.
79. Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, Masure HR (2000) Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun, 68, 5690-5.
80. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis, 175, 839-46.
81. Berry AM, Paton JC (2000) Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun, 68, 133-40.
82. Areas AP, Oliveira ML, Miyaji EN et al. (2004) Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun, 321, 192-6.
83. Wizemann TM, Heinrichs JH, Adamou JE et al. (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun, 69, 1593-8.
84. Adamou JE, Heinrichs JH, Erwin AL et al. (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun, 69, 949-58.
85. Lau GW, Haataja S, Lonetto M et al. (2001) A functional genomic analysis of type 3 Streptococcus pneumoniae virulence. Mol Microbiol 2001;40, 555-71
86. Polissi A, Pontiggia A, Feger G et al. (1998) Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect Immun, 66, 5620-9.
87. Kasper DL, Paoletti LC, Wessels MR et al. (1996) Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest, 98, 2308-14.
88. Baker CJ, Paoletti LC, Rench MA et al. (2000)Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis, 182, 1129-38.
89. Paoletti LC, Kasper DL (2002) Conjugate vaccines against group B streptococcus types IV and VII. J Infect Dis, 186, 123-6.
90. Brewer TF (2000) Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis, 31 (Suppl 3), S64-7.
91. Colditz GA, Brewer TF, Berkey CS et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA, 271, 698-702.
92. Fine PE (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis, 11 (Suppl 2), S353-9.
93. Nor NM, Musa M (2004) Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis (Edinb), 84, 102-9.
94. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2000) Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad. Sci USA, 97, 13853-8.
95. Pym AS, Brodin P, Majlessi L et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med, 9, 533-9.
96. Smith DA, Parish T, Stoker NG, Bancroft GJ. (2001) Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun, 69, 1142-50.
97. Delogu G, Li A, Repique C, Collins F, Morris SL (2002) DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun., 70, 292-302.
98. Palendira U, Kamath AT, Feng CG et al. (2002) Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun, 70, 1949-56.
99. McShane H, Brookes R, Gilbert SC, Hill AV (2001) Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun, 69, 681-6.
100. West D, Reddin K, Matheson M et al. (2001) Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun, 69, 1561-7.
101. Danve B, Lissolo L, Mignon M et al. (1993) Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine, 11, 1214-20.